FOXO4-DRI

FOXO4-DRI is a senolytic peptide designed to selectively induce apoptosis in senescent cells by disrupting the interaction between FOXO4 and p53 transcription factors. Developed at Erasmus University Medical Center in the Netherlands, it represents a targeted approach to eliminating senescent cells that accumulate with aging and contribute to tissue dysfunction.

In senescent cells, FOXO4 binds to and sequesters p53 in the nucleus, preventing p53 from triggering apoptosis and allowing senescent cells to persist despite their damaged state. FOXO4-DRI competitively interferes with this interaction, releasing p53 to activate apoptotic pathways specifically in senescent cells where FOXO4-p53 binding is elevated.

The D-retro-inverso design uses D-amino acids assembled in reverse sequence order, creating a peptide that maintains the spatial arrangement of side chains (and thus biological activity) while being highly resistant to proteolytic degradation. This provides extended stability compared to conventional L-peptides.

Animal studies have demonstrated FOXO4-DRI selectively kills senescent cells, improving markers of aging including fur regrowth, kidney function, and physical fitness in aged mice. These findings have generated substantial interest in senolytic approaches to aging, though translation to human applications requires further research into safety, dosing, and long-term effects of senescent cell clearance.